Juan C Garcia-Rubira

Dr. Juan C Garcia-Rubira

orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Circulation
Verified
Journal Article
Closed access
BIBorja Ibanez
Borja Ibanez
CMCarlos Macaya
Carlos Macaya
VSVicente Sánchez-Brunete
Vicente Sánchez-Brunete
GPGonzalo Pizarro
Gonzalo Pizarro
LFLeticia Fernández-Friera
Leticia Fernández-Friera
VFValentin Fuster
Valentin Fuster
Background—: The effect of β-blockers on infarct size when used in conjunction with primary percutaneous coronary intervention is unknown. We hypothesize that metoprolol reduces infarct size when administered early (intravenously before reperfusion). Methods and Results—: Patients with Killip class II or less anterior ST-segment–elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention within 6 hours of symptoms onset were randomized to receive intravenous metoprolol (n=131) or not (control, n=139) before reperfusion. All patients without contraindications received oral metoprolol within 24 hours. The predefined primary end point was infarct size on magnetic resonance imaging performed 5 to 7 days after STEMI. Magnetic resonance imaging was performed in 220 patients (81%). Mean±SD infarct size by magnetic resonance imaging was smaller after intravenous metoprolol compared with control (25.6±15.3 versus 32.0±22.2 g; adjusted difference, −6.52; 95% confidence interval, −11.39 to −1.78; P =0.012). In patients with pre–percutaneous coronary intervention Thrombolysis in Myocardial Infarction grade 0 to 1 flow, the adjusted treatment difference in infarct size was −8.13 (95% confidence interval, −13.10 to −3.16; P =0.0024). Infarct size estimated by peak and area under the curve creatine kinase release was measured in all study populations and was significantly reduced by intravenous metoprolol. Left ventricular ejection fraction was higher in the intravenous metoprolol group (adjusted difference, 2.67%; 95% confidence interval, 0.09–5.21; P =0.045). The composite of death, malignant ventricular arrhythmia, cardiogenic shock, atrioventricular block, and reinfarction at 24 hours in the intravenous metoprolol and control groups was 7.1% and 12.3%, respectively ( P =0.21). Conclusions—: In patients with anterior Killip class II or less ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention, early intravenous metoprolol before reperfusion reduced infarct size and increased left ventricular ejection fraction with no excess of adverse events during the first 24 hours after STEMI. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01311700. EUDRACT number: 2010-019939-35.

27 April 2011 in Heart
Verified
Journal Article
Open access
PDF file
ASAida Suárez-Barrientos
Aida Suárez-Barrientos
PLPedro López-Romero
Pedro López-Romero
DVDavid Vivas
David Vivas
FCFrancisco Castro-Ferreira
Francisco Castro-Ferreira
INIván J. Núñez-Gil
Iván J. Núñez-Gil
BIBorja Ibanez
Borja Ibanez
Background The circadian clock influences a number of cardiovascular (patho)physiological processes including the incidence of acute myocardial infarction. A circadian variation in infarct size has recently been shown in rodents, but there is no clinical evidence of this finding. Objective To determine the impact of time-of-day onset of ST segment elevation myocardial infarction (STEMI) on infarct size. Methods A retrospective single-centre analysis of 811 patients with STEMI admitted between 2003 and 2009 was performed. Infarct size was estimated by peak enzyme release. The relationship between peak enzyme concentrations and time-of-day were characterised using multivariate regression splines. Time of STEMI onset was divided into four 6-hour periods in phase with circadian rhythms. Results Model comparisons based on likelihood ratio tests showed a circadian variation in infarct size across time-of-day as evaluated by peak creatine kinase (CK) and troponin-I (TnI) concentrations (p=0.015 and p=0.012, respectively). CK and TnI curves described similar patterns across time, with a global maximum in the 6:00–noon period and a local minimum in the noon–18:00 period. Infarct size was largest in patients with STEMI onset in the dark-to-light transition period (6:00–noon), with an increase in peak CK and TnI concentrations of 18.3% (p=0.031) and 24.6% (p=0.033), respectively, compared with onset of STEMI in the 18:00–midnight period. Patients with anterior wall STEMI also had significantly larger infarcts than those with STEMI in other locations. Conclusions Significant circadian oscillations in infarct size were found in patients according to time-of-day of STEMI onset. The infarct size was found to be significantly larger with STEMI onset in the dark-to-light transition period (6:00–noon). If confirmed, these results may have a significant impact on the interpretation of clinical trials of cardioprotective strategies in STEMI.

1 October 2003 in Heart
Verified
Journal Article
Open access
PDF file
RMR Moreno
R Moreno
EGE Gordillo
E Gordillo
JZJ Zamorano
J Zamorano
CAC Almeria
C Almeria
JGJuan C Garcia-Rubira
Juan C Garcia-Rubira
CMC Macaya
C Macaya
Background: It is debatable whether surgical repair is routinely indicated in asymptomatic patients with left ventricular pseudoaneurysms. Objective: To evaluate the long term outcome of patients with pseudoaneurysm after myocardial infarction, focusing on those treated conservatively. Methods: 10 patients with postinfarction left ventricular pseudoaneurysm were followed up over a mean (SD) period of 3.8 (5.2) years. Results: In those treated conservatively (n = 9), cumulative survival was 88.9 (10.5)% and 74.1 (16.1)% at one and four years, respectively. The probability of being free of cardiac death was 88.9 (10.5)% at both one and four years. No patient had complete fatal heart rupture during follow up. Three patients suffered ischaemic stroke (at 1, 11, and 62 months). The cumulative incidence of ischaemic stroke was 10% at one year and 32.5% at four years. Conclusions: Long term outcome of patients with postinfarction left ventricular pseudoaneurysm is relatively benign, with a very low risk (none in this series) of fatal rupture. Taking into consideration the relatively high risk of stroke, chronic anticoagulant treatment could be considered.

11 April 2006 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
LILeopoldo Perez de Isla
Leopoldo Perez de Isla
JZJose Zamorano
Jose Zamorano
MQMaribel Quezada
Maribel Quezada
CACarlos Almería
Carlos Almería
JRJosé Luis Rodrigo
José Luis Rodrigo
CMCarlos Macaya
Carlos Macaya
Aims The development of mitral regurgitation (MR) after an acute myocardial infarction (AMI) is a recognized and frequent complication and its negative impact on survival has been observed. However, few data exist regarding MR after non-ST-segment elevation acute coronary syndrome (NSTSEACS). Our aim was to investigate the incidence, clinical predictors, and prognostic implications of MR in the setting of NSTSEACS. Methods and results We studied 300 consecutive patients (71.7% men, mean age 66.9±13 years) admitted to our coronary care unit for an NSTSEACS. Every patient underwent an echocardiographic study during the first week after the index NSTSEACS and was clinically followed up. MR was detected in 42% (126 patients; 88 men, mean age 71.3±11 years). Mean follow-up was 425.6±194.8 days. Only age and left ventricular (LV) ejection fraction (EF) were found as independent markers of the development of MR; no variable was found as an independent predictor of in-hospital mortality and only MR was found as an independent predictor of long-term outcome. Conclusion MR is frequent after an NSTSEACS. Age and a low LV EF are factors associated to its development. The presence and degree of MR confer a worse long-term prognosis to patients after a first NSTSEACS. Thus, the presence of MR should be specifically assessed in every patient after an NSTSEACS.

1 June 1994 in International Journal of Cardiology
Verified
Journal Article
Closed access
JGJuan C Garcia-Rubira
Juan C Garcia-Rubira
RHRafael Hidalgo
Rafael Hidalgo
JGJose Javier Gomez-Barrado
Jose Javier Gomez-Barrado
DRDolores Romero
Dolores Romero
JFJosém. Cruz Fernández
Josém. Cruz Fernández

1 November 2012 in Revista Española de Cardiología (English Edition)
Verified
Journal Article
Closed access
INIván J. Núñez-Gil
Iván J. Núñez-Gil
MMMaría Molina
María Molina
EBEsther Bernardo
Esther Bernardo
BIBorja Ibañez
Borja Ibañez
BRBorja Ruiz-Mateos
Borja Ruiz-Mateos
AFAntonio Fernández-Ortiz
Antonio Fernández-Ortiz